FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial…
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Repatha (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering…
Read More...
Read More...
